TENX · Tenax Therapeutics, Inc.
Market Cap
$79.71M
Shares
37.42M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.19
Open$2.13
Day$2.10–2.23
52W close$1.38–18.32
Avg vol 30d7.5M
Short int5.5M · 14.6% float · 1.0d
Short vol50%
Last earningsNov 13, 2025
DataJan 2024–Aug 2026
Filing10-Q · Jul 31
Raw chart and full-history price indicators begin at the captured split on Jan 3, 2024; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 31, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 14.5 · calm
Equity put/call 0.39
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−82%
below
Price vs 50-day avg
−80%
below
RSI (14)
25
oversold
MACD trend
Positive
52-week position
5%
near low
Momentum
relative strength
1-month return
−86%
trailing
6-month return
−80%
trailing
YTD return
−82%
this year
Relative strength
−94%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $11 › 200d $12 — 200d above 50d
Institutional flow
Accumulating
+43% holders QoQ · +45 funds added
Insider flow
Accumulating
Net +$1.8M over 90 days · 0% sells
Short interest
Rising
14.63% of float · ▲ +114.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
114 holders — near 3-yr high, broad support
Squeeze score
55
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
−17%
Y/Y
Free cash flow
$-35.8M
Quant / Vol
risk profile
Volatility
124%
annualized · 1-yr
Max drawdown
−92%
past year
ATR
40.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−82%
Bearish
Price vs 50-day avg
−80%
Bearish
RSI (14)
25
Neutral
MACD trend
Positive
Bullish
52-week position
5%
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $11 › 200d $12 — 200d above 50d
Institutional flow
Accumulating
+43% holders QoQ · +45 funds added
Insider flow
Accumulating
Net +$1.8M over 90 days · 0% sells
Short interest
Rising
14.63% of float · ▲ +114.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
114 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $2 · 5%
Range high $18
vs 200-day avg -82%
vs 50-day avg -80%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TENX
this stock
Tenax Therapeutics, Inc.
|
$79.71M | -82.0% | -86.7% | — | 14.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.8% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.27B | +4.6% | +20.8% | 19.6 | 2.3% |
|
ARGX
Argenx SE
|
$65.12B | +25.9% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.92B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Jan 3, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TENX | +23.0% | -85.5% | -79.5% | -84.0% | -82.0% |
| SPY | +1.1% | +4.0% | +14.7% | +3.2% | +13.1% |
| vs SPY | +21.9% | -89.5% | -94.2% | -87.2% | -95.1% |
Key facts
CIK
34956
CUSIP
88032L605
13F (30d)
115 filings
110 filers
Visit website
Investor relations